2-47800174-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.2191C>T(p.Gln731*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 5 Pathogenic:1
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
Lynch syndrome Pathogenic:1
Coding sequence variation resulting in a stop codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln731*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in several individuals suspected to have Lynch syndrome (PMID: 10508506, 16736289, 26517685). ClinVar contains an entry for this variant (Variation ID: 89261). Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q731* pathogenic mutation (also known as c.2191C>T), located in coding exon 4 of the MSH6 gene, results from a C to T substitution at nucleotide position 2191. This changes the amino acid from a glutamine to a stop codon within coding exon 4. This mutation was identified in two related individuals diagnosed with colon cancer at ages 48 and 49 respectively, though the family did not meet ACI or ACII criteria (Wijnen J, Nat. Genet. 1999 Oct; 23(2):142-4; Hendriks YM, Gastroenterology 2004 Jul; 127(1):17-25). This mutation was also identified in a female diagnosed with MSI-stable endometrial cancer at age 56, as well as breast cancer at age 50 (Jóri B, Oncotarget 2015 Dec; 6(38):41108-22). In addition to the clinical data presented in the literature, since premature stop codons are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at